

SCIENCE NEWS TODAY

Friday, July 22, 2016

GET RSS FEED

SUBMIT RELEASE

articles: 336,334,314
readers: 3,789,636
Russia Loses Appeal of Olympics Ban

EIN PRESSWIRE

Reach over 5,000,000
people with
one click

LEARN MORE ►

Submit a press release · See all

EIN NEWSFEED MAKER

Get Professional-Quality
News Delivered to
Your Website or Blog
24 Hours a Day


search now

LEARN MORE ►

4th Great Mekong Subregion
(Myanmar) Power Summit
2016

29 Nov - 1 Dec, 2016
Sule Shangri-La Hotel Yangon, Myanmar

The once-isolated country has embraced their new
government, and is getting down to setting in motion
reforms for more FDI in Burma's energy sector...



EVENTS & CONFERENCES

EIN Newsdesk is a "Go-To" destination for
journalists and other professionals
world-wide who are deeply involved in very
specific topics. Our vertical niche
publications reach industry leaders and
decision makers who meet at conferences.
Upload your event today.

Got News to Share?



Send 2 FREE Releases



Menu > All News Topics > Science News Topics: By Country | By State ; Press Releases by Industry Channel > All Science Press Releases

EIN PRESSWIRE

MedGenome to present its tumor microenvironment analysis results at the AACR Cancer Immunotherapy Conference in New York

The analysis compares the immune microenvironment of uveal melanoma and skin cutaneous melanoma

FOSTER CITY, CALIFORNIA, UNITED STATES, July 21, 2016 /EINPresswire.com/ -- MedGenome will be presenting its analysis comparing the immune microenvironment of uveal melanoma and skin cutaneous melanoma at the Second CRI-CIMT-EAT-AACR International Cancer Immunotherapy Conference, September 25-28, 2016, New York.



The remarkable success of checkpoint control inhibitors in treating a variety of different cancers has necessitated a deeper assessment of the tumor and its microenvironment at the genetic and phenotypic level. Data from recent clinical trials has unequivocally established that the tumor microenvironment significantly impacts the efficacy of immune-oncology drugs.

The study, which compared the **tumor microenvironments** of uveal melanoma vs skin cutaneous melanoma, involved a gene expression signature-based approach to qualitatively and quantitatively assess the epithelial, stromal and immune content of tumors from RNA-seq data. The immune cell content of the tumors was further stratified to determine the infiltration pattern of nine different immune cell types in the tumor. These signatures were then applied singly, or in combination on the TCGA RNA-seq data from 33 cancers.

And the study results suggest that gene expression signatures can address a critical unmet need in the immune-oncology space, which is to create a framework for treating tumors that carry less mutation burden combined with poor T-cell infiltration. The results also propose that therapies targeting MDSC cells, or those that can shift the balance towards increased M1 content over M2 are likely to show efficacy in Uveal melanoma, which are unresponsive to checkpoint inhibitor antibodies.

About MedGenome

MedGenome (<http://www.medgenome.com>) is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual's genome. Its unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized health care. MedGenome is a market leader for genomic diagnostics in South Asia and a leading provider of **genomics research services** globally. It is also a founding member of GenomeAsia 100K initiative to sequence 100,000 genomes in South, North and East Asia.

Our NGS lab in Foster City, California is ISO 15189 compliant, CLIA certified and CAP accredited.

Forward-looking Statements:

This document contains certain forward-looking statements, other than the statements of research facts contained in this press release are forward looking statements. Terms such as "believe", "estimate", "anticipate", "plan", "predict", "may", "hope", "can", "will", "should", "expect", "intend", "is designed to", "with the intent", "potential", the negative of these words or such other variations thereon or comparable terminology, may indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements speak only as of the date of this press release. The events and circumstances reflected in MedGenome's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, MedGenome does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Hiranjith GH
MedGenome
[email us here](#)
6504253839



Blog | Stories | Media | Careers | Events | Sitemap | Contact



TOLL FREE
1800 102 8401

EMAIL US
contact@medgenome.com

Market leader for
genetic
diagnostic testing
in India and a
leading provider
of genomic
research services
globally

Powered by **EIN PRESSWIRE**

Distribution channels: Companies, Healthcare & Pharmaceuticals ...
[Submit your press release](#)

News Topics

- All News Topics
- Science News Topics
- Science News by Country

Newsletters

- Create Newsletter
- Search Newsletters
- Browse Newsletters

Press Releases

- Submit Release
- Browse Featured Releases
- Browse All Releases

Events & Conferences

- Create Event
- Search Events
- Browse Events

RSS Feeds

- Create RSS Feed
- Search RSS Feeds
- Browse RSS Feeds

Other Services

- World Media Directory
- NewsPlugin for Wordpress
- Blog Op/Ed

Questions?

- About EIN Newsdesk
- How-to Videos
- User Agreement
- Privacy Policy
- Contact

- Login
- Sign Up